Trial Profile
A Trial Investigating the Pharmacodynamic Response of NN5401 in Subjects With Type 1 Diabetes.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2017
Price :
$35
*
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novo Nordisk
- 26 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 19 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Dec 2009 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.